Get the Stockscreener App
33.15
0.15%
0.05
Royalty Pharma Plc stock is traded at $33.15, with a volume of 4.35M.
It is up +0.15% in the last 24 hours and up +2.73% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$33.10
Open:
$33.22
24h Volume:
4.35M
Relative Volume:
0.98
Market Cap:
$14.26B
Revenue:
$2.27B
Net Income/Loss:
$1.15B
P/E Ratio:
13.00
EPS:
2.55
Net Cash Flow:
$2.80B
1W Performance:
+0.79%
1M Performance:
+2.73%
6M Performance:
+26.48%
1Y Performance:
+18.52%
1-Day Range:
$33.03
$33.72
1-Week Range:
$31.97
$34.11
52-Week Range:
$24.05
$34.20
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
33.15 | 14.26B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Bridgefront Capital LLC Acquires New Shares in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
1,644,804 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by BNP Paribas Financial Markets - MarketBeat
Dimensional Fund Advisors LP Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Price T Rowe Associates Inc. MD - MarketBeat
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan - MSN
Corton Capital Inc. Invests $278,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Q1 2025 slides: double-digit growth drives raised guidance - Investing.com Nigeria
Royalty Pharma Reports Strong Q1 2025 Growth - TipRanks
Royalty Pharma Q1 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma’s Earnings Call: Growth and Optimism - TipRanks
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Schonfeld Strategic Advisors LLC - MarketBeat
AlTi Global Inc. Buys Shares of 387,567 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Q1 2025 slides: double-digit growth drives raised guidance By Investing.com - Investing.com South Africa
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Earnings call transcript: Royalty Pharma Q1 2025 misses EPS estimates - Investing.com
Royalty Pharma plc SEC 10-Q Report - TradingView
Royalty Pharma earnings missed by $0.66, revenue fell short of estimates - Investing.com UK
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates - Yahoo Finance
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Royalty Pharma Reports First Quarter 2025 Results - TradingView
Cutter Capital Management LP Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Reports 17% Growth in Portfolio Receipts to $839 Million and Raises 2025 Financial Guidance - Nasdaq
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 - The Globe and Mail
Caisse DE Depot ET Placement DU Quebec Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
AQR Capital Management LLC Boosts Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
MML Investors Services LLC Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Northern Trust Corp Purchases 376,619 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
ArrowMark Colorado Holdings LLC Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Projected to Post Earnings on Thursday - MarketBeat
PDT Partners LLC Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Hsbc Holdings PLC Sells 30,304 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics - Nasdaq
Royalty Pharma plc (NASDAQ:RPRX) Holdings Boosted by Regal Partners Ltd - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Tudor Investment Corp ET AL - MarketBeat
First Trust Advisors LP Decreases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Wells Fargo & Company MN Buys 15,790 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Moody’s upgrades Royalty Pharma’s rating, maintains stable outlook By Investing.com - Investing.com Nigeria
Moody’s upgrades Royalty Pharma’s rating, maintains stable outlook - Investing.com Australia
Walleye Capital LLC Buys Shares of 25,124 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Uniplan Investment Counsel Inc. Buys New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Dark Forest Capital Management LP - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by GMT Capital Corp - MarketBeat
Barclays PLC Acquires 54,421 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):